Investment Partners Ltd. OH ADV boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,865 shares of the company’s stock after acquiring an additional 426 shares during the quarter. Johnson & Johnson comprises 1.8% of Investment Partners Ltd. OH ADV’s holdings, making the stock its 15th largest holding. Investment Partners Ltd. OH ADV’s holdings in Johnson & Johnson were worth $1,966,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of JNJ. Kelman Lazarov Inc. raised its position in Johnson & Johnson by 2.8% in the second quarter. Kelman Lazarov Inc. now owns 7,469 shares of the company’s stock valued at $988,000 after purchasing an additional 200 shares during the period. Villere ST Denis J & Co. LLC lifted its stake in shares of Johnson & Johnson by 10.4% in the 2nd quarter. Villere ST Denis J & Co. LLC now owns 59,850 shares of the company’s stock valued at $7,917,000 after purchasing an additional 5,635 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH lifted its stake in shares of Johnson & Johnson by 70.5% in the 2nd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 431,402 shares of the company’s stock valued at $57,113,000 after purchasing an additional 178,417 shares during the last quarter. Northwest Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Northwest Wealth Management LLC now owns 2,812 shares of the company’s stock valued at $372,000 after purchasing an additional 45 shares during the last quarter. Finally, Gilbert & Cook Inc. lifted its stake in shares of Johnson & Johnson by 87.3% in the 2nd quarter. Gilbert & Cook Inc. now owns 7,365 shares of the company’s stock valued at $975,000 after purchasing an additional 3,432 shares during the last quarter. 65.90% of the stock is owned by institutional investors.

In related news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.

Shares of Johnson & Johnson (JNJ) traded up 0.83% during trading on Monday, hitting $131.09. The stock had a trading volume of 2,243,130 shares. The stock’s 50-day moving average price is $132.79 and its 200-day moving average price is $129.43. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The company has a market cap of $351.85 billion, a P/E ratio of 22.18 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the company earned $1.74 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.58%. Johnson & Johnson’s payout ratio is currently 56.76%.

COPYRIGHT VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/johnson-johnson-jnj-holdings-raised-by-investment-partners-ltd-oh-adv/1603634.html.

Several analysts recently issued reports on JNJ shares. BTIG Research lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price objective on the stock. in a report on Friday, July 21st. Atlantic Securities cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price on the stock. in a research report on Friday, July 21st. Alembic Global Advisors lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Finally, Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a research note on Monday, September 18th. Six research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $135.52.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.